Skip to main content

Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730).

Publication ,  Journal Article
Lilenbaum, RC; Herndon, JE; List, MA; Desch, C; Watson, DM; Miller, AA; Graziano, SL; Perry, MC; Saville, W; Chahinian, P; Weeks, JC ...
Published in: J Clin Oncol
January 1, 2005

PURPOSE: We compared the efficacy of combination chemotherapy versus single-agent therapy in patients with advanced non-small-cell lung cancer. PATIENTS AND METHODS: A total of 561 eligible patients were randomly assigned to receive paclitaxel alone or in combination with carboplatin. RESULTS: The response rate was 17% in the paclitaxel arm and 30% in the carboplatin-paclitaxel arm (P < .0001). Median failure-free survival was 2.5 months in the paclitaxel arm and 4.6 months in the carboplatin-paclitaxel arm (P = .0002). Median survival times were 6.7 months (95% CI, 5.8 to 7.8) and 8.8 months (95% CI, 8.0 to 9.9), and 1-year survival rates were 32% (95% CI, 27% to 38%), and 37% (95% CI, 32% to 43%), respectively. The overall survival distributions were not statistically different: hazard ratio = 0.91 (95% CI, 0.77 to 1.17; P = .25). Hematological toxicity and nausea were more frequent in the combination arm, but febrile neutropenia and toxic deaths were equally low in both arms. There was no significant survival difference in elderly patients. Performance status 2 patients treated with combination chemotherapy had a better survival rate than those treated with single-agent therapy (P = .019). CONCLUSION: Combination chemotherapy improves response rate and failure-free survival compared with single-agent therapy, but there was no statistically significant difference in the primary end point of overall survival. The results in elderly patients were similar to younger patients. Performance status 2 patients had a superior outcome when treated with combination chemotherapy.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Clin Oncol

DOI

ISSN

0732-183X

Publication Date

January 1, 2005

Volume

23

Issue

1

Start / End Page

190 / 196

Location

United States

Related Subject Headings

  • Survival Rate
  • Paclitaxel
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Lung Neoplasms
  • Humans
  • Female
  • Carcinoma, Non-Small-Cell Lung
  • Carboplatin
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lilenbaum, R. C., Herndon, J. E., List, M. A., Desch, C., Watson, D. M., Miller, A. A., … Green, M. R. (2005). Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol, 23(1), 190–196. https://doi.org/10.1200/JCO.2005.07.172
Lilenbaum, Rogerio C., James E. Herndon, Marcy A. List, Chris Desch, Dorothy M. Watson, Antonius A. Miller, Stephen L. Graziano, et al. “Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730).J Clin Oncol 23, no. 1 (January 1, 2005): 190–96. https://doi.org/10.1200/JCO.2005.07.172.
Lilenbaum RC, Herndon JE, List MA, Desch C, Watson DM, Miller AA, et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol. 2005 Jan 1;23(1):190–6.
Lilenbaum, Rogerio C., et al. “Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730).J Clin Oncol, vol. 23, no. 1, Jan. 2005, pp. 190–96. Pubmed, doi:10.1200/JCO.2005.07.172.
Lilenbaum RC, Herndon JE, List MA, Desch C, Watson DM, Miller AA, Graziano SL, Perry MC, Saville W, Chahinian P, Weeks JC, Holland JC, Green MR. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol. 2005 Jan 1;23(1):190–196.

Published In

J Clin Oncol

DOI

ISSN

0732-183X

Publication Date

January 1, 2005

Volume

23

Issue

1

Start / End Page

190 / 196

Location

United States

Related Subject Headings

  • Survival Rate
  • Paclitaxel
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Lung Neoplasms
  • Humans
  • Female
  • Carcinoma, Non-Small-Cell Lung
  • Carboplatin